Abstract:BACKGROUND & OBJECTIVE:Cellular keratin, an indicator for cancer cell in circulation gains increasing attention. Although CK19mRNA as a gene marker used to identify micro-metastasis is of relatively high practical value, it lacks specificity and sensitivity in diagnosis of cancer. The aim of this study is to evaluate whether the combined detection of CK19mRNA with other tumor markers, such as carcinoembryanic antigen(CEA), neuron-specific Enolase(NSE), tissue polypeptide antigen(TPA), would improve the diagnosis of lung cancer. METHODS:The expression level of CK19mRNA in peripheral blood mononucleated cells (PBMCS) was determined by RT-PCR, The levels of CEA, NSE, and TPA in serum were determined by enzyme-linked immunosorbent assay (ELISA) and time-resolved fluorometry(TRF) in 91 patients with lung cancer, 33 with benign lung diseases (BLD) and 50 healthy controls. The data was analyzed by t test and chi 2 test. RESULTS:The positive rates of CK19mRNA, CEA, NSE, and TPA in lung cancer group (49.5%, 65.9%, 67.0%, and 83.5%, respectively) were remarkably higher than in BLD group(24.2%, 9.0%, 15.2%, and 9.0%, respectively) and in healthy control group (10.0%, 4.0%, 8.0%, and 6.0%, respectively) (P < 0.01). The positive rate of CK19mRNA was not statistically different in various histological subtypes (P > 0.05). Although the positive rate of CK19mRNA appeared to be associated with the clinical stage (stage I + II: 44.4%, stage III: 48.4%, stag IV: 54.2%), there was no statistical significance among the three groups (P > 0.05). The serum level (microgram/L)/positive rate of CEA(3.5/27.8%, 5.1/35.5%, and 8.5/58.3%, respectively), NSE (12.5/33.3%, 15.3/41.9%, and 24.7/58.3%, respectively), and TPA (1.1/44.4%, 1.8/58.1%, and 3.6/66.7%, respectively) in stage I + II, III, and IV appeared to be associated with the clinical stages of lung cancer, but no statistical significance among the three groups (P > 0.05). Combined detection of three or four tumor markers yielded significant higher effective accuracy in diagnosis of lung cancer than that of any of two tumor markers or single tumor marker (P < 0.05). In addition, the results showed that TPA, CEA, and NSE were relatively specific for squamous cell carcinoma (76.7%), adenocarcinomas (83.3%), and small-cell lung cancer (79.2%), respectively. CONCLUSION:The combined measurement of CK19mRNA with CEA, NSE, and TPA can increase diagnosis rate of lung cancer, can also provide potent diagnosis basis for treatment.

Diagnostic Value of Serum 7-AABs Combined with CEA and CA199 in the Detection of Lung Cancer

The clinical value of combined detection of seven lung cancer-related autoantibodies in assisting the diagnosis of non-small-cell lung cancer

Clinical Value of Seven Autoantibodies Against Tumor-Associated Antigens and Tumor Markers in Lung Cancer Patients: A Retrospective Analysis from a Single Institution

Application Value Analysis of Seven-Autoantibody Panel in the Lung Cancer Screening in Yunnan

Diagnostic value of multiple tumor-associated autoantibodies in lung cancer

The Diagnostic Value of a Seven‐autoantibody Panel and a Nomogram with a Scoring Table for Predicting the Risk of Non–small‐cell Lung Cancer

Early Detection of Lung Cancer by Using an Autoantibody Panel in Chinese Population

Seven tumor‐associated autoantibodies as a serum biomarker for primary screening of early‐stage non‐small cell lung cancer

Value of joint detection of tumor markers to the diagnosis of lung cancer

Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis

B-360 Usefulness of the Ratios of CYFRA21-1 and P53 Autoantibody Immune Complexes to Their Free Antigens in Lung Cancer

[Significance of Combined Determination of CK19mRNA, Carcinoembryanic Antigen, Neuron-Specific Enolase, and Tissue Polypeptide Antigen in Peripheral Blood of Patients with Lung Cancer].

Five Tumor-Associated Autoantibodies Expression Levels in Serum Predict Lung Cancer and Associate with Poor Outcome.

DIAGNOSTIC VALUE OF SERUM TUMOR MARKERS FOR LUNG CANCER

The combination of a seven-autoantibody panel with computed tomography scanning can enhance the diagnostic efficiency of non-small cell lung cancer

The value of combined detection of CEA, CYFRA21-1, SCC-Ag, and pro-GRP in the differential diagnosis of lung cancer

[The value of serum tumor marker in the diagnosis of lung cancer]

Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer

Early Detection of Lung Cancer in a Real-World Cohort Via Tumor-Associated Immune Autoantibody and Imaging Combination

Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?

Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma in situ